The Imaging segment at GE HealthCare is dedicated to advancing medical imaging technologies, encompassing molecular imaging, computed tomography (CT), magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems. This segment focuses on developing AI-enabled solutions to enhance diagnostic accuracy and efficiency. R&D efforts are directed towards improving image quality, reducing radiation exposure, and streamlining clinical workflows. The segment's technologies play a crucial role in early disease detection, treatment planning, and monitoring patient outcomes across various therapeutic areas, including oncology, cardiology, and neurology. GE HealthCare's imaging solutions aim to provide clinicians with the tools they need to deliver precision care and improve patient outcomes.

GE HealthCare's Ultrasound segment provides a comprehensive range of ultrasound solutions for screening, diagnosis, treatment, and monitoring of diseases. This includes radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The segment's R&D activities focus on developing advanced imaging techniques, such as elastography and contrast-enhanced ultrasound, to improve diagnostic accuracy and expand clinical applications. Ultrasound technologies are used in various therapeutic areas, including obstetrics, cardiology, and musculoskeletal imaging. GE HealthCare's ultrasound solutions aim to provide clinicians with real-time imaging capabilities, enabling them to make informed decisions and improve patient outcomes.

The Patient Care Solutions segment at GE HealthCare is involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. This segment focuses on developing integrated solutions that improve patient safety, enhance clinical efficiency, and optimize patient outcomes. R&D efforts are directed towards developing advanced monitoring technologies, such as wearable sensors and remote monitoring systems, to enable continuous patient surveillance and early detection of adverse events. The segment's technologies are used in various clinical settings, including hospitals, intensive care units, and home healthcare environments. GE HealthCare's patient care solutions aim to provide clinicians with the tools they need to deliver personalized care and improve patient outcomes.

GE HealthCare's Pharmaceutical Diagnostics segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. R&D efforts are focused on developing novel contrast agents with improved safety profiles and enhanced imaging capabilities. The segment's products play a crucial role in improving diagnostic accuracy and enabling personalized treatment decisions across various therapeutic areas, including oncology, cardiology, and neurology.